Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714596 | 0.84 | CYP19A1 (0.44) | ALDH1A1CYP19A1 | |
| SCHEMBL20274484 | 0.77 | RORC (0.43) | RORCSTSOPRD1OPRK1JAK2 | |
| SCHEMBL20274598 | 0.76 | CYP19A1 (0.47) | ALDH1A1CYP19A1 | |
| SCHEMBL16724579 | 0.76 | CYP19A1 (0.47) | ALDH1A1CYP19A1 | |
| SCHEMBL22950454 | 0.74 | RORC (0.42) | RORCSTSOPRD1OPRK1JAK2 | |
| SCHEMBL29471673 | 0.74 | RORC (0.41) | RORCSTSOPRD1OPRK1JAK2 | |
| SCHEMBL22950459 | 0.72 | OPRD1 (0.45) | RORCSTSOPRD1OPRK1JAK2 | |
| SCHEMBL29662090 | 0.72 | OPRD1 (0.45) | RORCSTSOPRD1OPRK1JAK2 | |
| SCHEMBL20722455 | 0.71 | RORC (0.47) | RORCSTSOPRD1OPRK1JAK2 | |
| SCHEMBL13657954 | 0.71 | RORC (0.47) | RORCSTSOPRD1OPRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2015075598-A1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141402-A1 | PURINE DERIVATIVES | ADORA3, ADORA1, HPRT1 | RORC 2392/4885STS 4322/4885OPRD1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.